Elekta collaborates with New York-based MSK to continue development of clinical protocols for MR-linac technology

Elekta has entered into a research agreement with Memorial Sloan Kettering Cancer Center (MSK), a world leader in patient care, research and education programmes, located in New York City, through which MSK will use an MR-linac system to investigate new treatment standards, imaging protocols, and treatment planning methodologies across various cancer indications.
PharmaBiz

One Response to “Elekta collaborates with New York-based MSK to continue development of clinical protocols for MR-linac technology”

  1. John Gooderham

    I’m pleased to hear of Elekta’s development with MSK, and the progress for cancer patients that will result. I still wonder why Elekta, who manufacture in West Sussex – the only county in England where linacs are produced – won’t respond to my emails about West Sussex – the only county in England with any radiotherapy facilities for patients.